Clarus Lifesciences II SC 13D/A Ophthotech Corp.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C.  20549

SCHEDULE 13D
 

Under the Securities Exchange Act of 1934

(Amendment No. 1)*

Ophthotech Corporation

(Name of Issuer)

Common Stock, $.001 par value per share

(Title of Class of Securities)

683745103

(CUSIP Number)

Robert Liptak

Clarus Ventures, LLC

101 Main Street, Suite 1210, Cambridge, MA 02142

(617) 949-2200

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

February 18, 2014

(Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. o

Note:  Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits.  See §240.13d-7 for other parties to whom copies are to be sent.

*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP NO.    683745103  13D Page 2 of 15 Pages 

1	NAMES OF REPORTING PERSONS.  I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY).  Clarus Lifesciences II, L.P.
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)        (a)  o                                                                                                                                                                      (b)  x
3	SEC USE ONLY
4	SOURCE OF FUNDS (SEE INSTRUCTIONS)  WC
5	CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) o
6	CITIZENSHIP OR PLACE OF ORGANIZATION  Delaware
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		7	SOLE VOTING POWER  0 shares
		8	SHARED VOTING POWER  3,054,744 shares
		9	SOLE DISPOSITIVE POWER  0 shares
		10	SHARED DISPOSITIVE POWER  3,054,744 shares
11	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  3,054,744 shares
12	CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) o
13	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  9.2%1
14	TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)  PN

_________________

1 Percentage calculated using a denominator of 33,318,575 shares of Common Stock of the Issuer as of February 18, 2014.

CUSIP NO.    683745103  13D Page 3 of 15 Pages 

1	NAMES OF REPORTING PERSONS.  I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY).  Clarus Ventures II GP, L.P.
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)        (a)  o                                                                                                                                                                      (b)  x
3	SEC USE ONLY
4	SOURCE OF FUNDS (SEE INSTRUCTIONS)  AF
5	CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) o
6	CITIZENSHIP OR PLACE OF ORGANIZATION  Delaware
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		7	SOLE VOTING POWER  0 shares
		8	SHARED VOTING POWER  3,054,744 shares
		9	SOLE DISPOSITIVE POWER  0 shares
		10	SHARED DISPOSITIVE POWER  3,054,744 shares
11	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  3,054,744 shares
12	CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) o
13	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  9.2%2
14	TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)  PN

____________

2 Percentage calculated using a denominator of 33,318,575 shares of Common Stock of the Issuer as of February 18, 2014.

CUSIP NO.    683745103  13D Page 4 of 15 Pages 

1	NAMES OF REPORTING PERSONS.  I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY).  Clarus Ventures II, LLC
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)        (a)  o                                                                                                                                                                      (b)  x
3	SEC USE ONLY
4	SOURCE OF FUNDS (SEE INSTRUCTIONS)  AF
5	CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) o
6	CITIZENSHIP OR PLACE OF ORGANIZATION  Delaware
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		7	SOLE VOTING POWER  0 shares
		8	SHARED VOTING POWER  3,054,744 shares
		9	SOLE DISPOSITIVE POWER  0 shares
		10	SHARED DISPOSITIVE POWER  3,054,744 shares
11	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  3,054,744 shares
12	CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) o
13	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  9.2%3
14	TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)  PN

________________

3 Percentage calculated using a denominator of 33,318,575 shares of Common Stock of the Issuer as of February 18, 2014.

CUSIP NO.    683745103  13D Page 5 of 15 Pages 

1	NAMES OF REPORTING PERSONS.  I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY).  Robert Liptak
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)        (a)  o                                                                                                                                                                      (b)  x
3	SEC USE ONLY
4	SOURCE OF FUNDS (SEE INSTRUCTIONS)  AF
5	CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) o
6	CITIZENSHIP OR PLACE OF ORGANIZATION  United States citizen
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		7	SOLE VOTING POWER  0 shares
		8	SHARED VOTING POWER  3,054,744 shares
		9	SOLE DISPOSITIVE POWER  0 shares
		10	SHARED DISPOSITIVE POWER  3,054,744 shares
11	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  3,054,744 shares
12	CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) o
13	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  9.2%4
14	TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)  IN

________________

4 Percentage calculated using a denominator of 33,318,575 shares of Common Stock of the Issuer as of February 18, 2014.

CUSIP NO.    683745103  13D Page 6 of 15 Pages 

1	NAMES OF REPORTING PERSONS.  I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY).  Nicholas Simon
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)        (a)  o                                                                                                                                                                      (b)  x
3	SEC USE ONLY
4	SOURCE OF FUNDS (SEE INSTRUCTIONS)  AF
5	CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) o
6	CITIZENSHIP OR PLACE OF ORGANIZATION  United States citizen
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		7	SOLE VOTING POWER  0 shares
		8	SHARED VOTING POWER  3,054,744 shares
		9	SOLE DISPOSITIVE POWER  0 shares
		10	SHARED DISPOSITIVE POWER  3,054,744 shares
11	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  3,054,744 shares
12	CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) o
13	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  9.2%5
14	TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)  IN

________________

5 Percentage calculated using a denominator of 33,318,575 shares of Common Stock of the Issuer as of February 18, 2014.

CUSIP NO.    683745103  13D Page 7 of 15 Pages 

1	NAMES OF REPORTING PERSONS.  I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY).  Nicholas Galakatos
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)        (a)  o                                                                                                                                                                      (b)  x
3	SEC USE ONLY
4	SOURCE OF FUNDS (SEE INSTRUCTIONS)  AF
5	CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) o
6	CITIZENSHIP OR PLACE OF ORGANIZATION  United States citizen
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		7	SOLE VOTING POWER  8,060 shares
		8	SHARED VOTING POWER  3,054,744 shares
		9	SOLE DISPOSITIVE POWER  8,060 shares
		10	SHARED DISPOSITIVE POWER  3,054,744 shares
11	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  3,062,804 shares
12	CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) o
13	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  9.2%6
14	TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)  IN

________________

6 Percentage calculated using a denominator of 33,318,575 shares of Common Stock of the Issuer as of February 18, 2014 and 3,060 shares of Common Stock underlying options that are exercisable as of January 31, 2014, or will become exercisable within 60 days after such date.

CUSIP NO.    683745103  13D Page 8 of 15 Pages 

1	NAMES OF REPORTING PERSONS.  I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY).  Dennis Henner
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)        (a)  o                                                                                                                                                                      (b)  x
3	SEC USE ONLY
4	SOURCE OF FUNDS (SEE INSTRUCTIONS)  AF
5	CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) o
6	CITIZENSHIP OR PLACE OF ORGANIZATION  United States citizen
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		7	SOLE VOTING POWER  0 shares
		8	SHARED VOTING POWER  3,054,744 shares
		9	SOLE DISPOSITIVE POWER  0 shares
		10	SHARED DISPOSITIVE POWER  3,054,744 shares
11	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  3,054,744 shares
12	CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) o
13	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  9.2%7
14	TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)  IN

________________

7 Percentage calculated using a denominator of 33,318,575 shares of Common Stock of the Issuer as of February 18, 2014.

CUSIP NO.    683745103  13D Page 9 of 15 Pages 

1	NAMES OF REPORTING PERSONS.  I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY).  Kurt Wheeler
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)        (a)  o                                                                                                                                                                      (b)  x
3	SEC USE ONLY
4	SOURCE OF FUNDS (SEE INSTRUCTIONS)  AF
5	CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) o
6	CITIZENSHIP OR PLACE OF ORGANIZATION  United States citizen
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		7	SOLE VOTING POWER  0 shares
		8	SHARED VOTING POWER  3,054,744 shares
		9	SOLE DISPOSITIVE POWER  0 shares
		10	SHARED DISPOSITIVE POWER  3,054,744 shares
11	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  3,054,744 shares
12	CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) o
13	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  9.2%8
14	TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)  IN

________________

8 Percentage calculated using a denominator of 33,318,575 shares of Common Stock of the Issuer as of February 18, 2014.

CUSIP NO.    683745103  13D Page 10 of 15 Pages 

1	NAMES OF REPORTING PERSONS.  I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY).  Michael Steinmetz
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)        (a)  o                                                                                                                                                                      (b)  x
3	SEC USE ONLY
4	SOURCE OF FUNDS (SEE INSTRUCTIONS)  AF
5	CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) o
6	CITIZENSHIP OR PLACE OF ORGANIZATION  German citizen
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		7	SOLE VOTING POWER  0 shares
		8	SHARED VOTING POWER  3,054,744 shares
		9	SOLE DISPOSITIVE POWER  0 shares
		10	SHARED DISPOSITIVE POWER  3,054,744 shares
11	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  3,054,744 shares
12	CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) o
13	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  9.2%9
14	TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)  IN

________________

9 Percentage calculated using a denominator of 33,318,575 shares of Common Stock of the Issuer as of February 18, 2014.

CUSIP NO.    683745103  13D Page 11 of 15 Pages 

Schedule 13D

Item 1.             Security and Issuer.

This Amendment No. 1 to the statement on Schedule 13D (this “Amendment No. 1”) amends and supplements the statement on Schedule 13D filed on November 20, 2013 (the “Original 13D,” and, together with Amendment No. 1, the “Schedule 13D”) filed by the Reporting Persons, and relates to common stock $.001 par value (the “Common Stock”) of Ophthotech Corporation (the “Issuer”) having its principal executive office at One Penn Plaza, 35th Floor, New York, New York 10119.  This Amendment No. 1 is being filed to disclose the change in beneficial ownership of the Issuer’s Common Stock by the Reporting Persons in connection with an underwriter public offering of the Issuer’s Common Stock which closed on February 18, 2014 (the “Offering”).

Except as specifically provided herein, this Amendment No. 1 does not modify any of the information previously reported on the Original 13D.  All capitalized terms contained herein but not otherwise defined shall have the meanings ascribed to such terms in the Original 13D.

Item 2.             Identity and Background.

This statement is being filed by:

(a) Clarus Lifesciences II, L.P. (the “Fund”);

(b) Clarus Ventures II GP, L.P. (“Clarus GP”), which is the sole general partner of the Fund; and Clarus Ventures II, LLC (“Clarus GPLLC” and, together with Clarus GP, the “Control Entities”), which is the sole general partner of Clarus GP; and

(c) Robert Liptak, Nicholas Simon, Nicholas Galakatos, Dennis Henner, Kurt Wheeler and Michael Steinmetz (together, the “Managing Directors”).  The Managing Directors are the directors of Clarus GPLLC.

The persons named in this Item 2 are referred to individually herein as a “Reporting Person” and collectively as the “Reporting Persons.”  The Reporting Persons have entered into a Joint Filing Agreement, dated as of the date hereof, a copy of which is filed with this Schedule 13D as Exhibit 99.1 (which is incorporated herein by reference), pursuant to which the Reporting Persons have agreed to file this statement jointly in accordance with the provisions of Rule 13d-1(k) under the Act.

Item 3.            Source and Amount of Funds or Other Consideration.

This Amendment No. 1 amends and supplements Item 3 of the Original 13D as set forth below:

As of January 31, 2014, Nicholas Galakatos held 3,060 shares of Common Stock underlying options that are exercisable as of such date, or that will become exercisable within 60 days of such date.

Item 5.            Interest in Securities of the Issuer.

This Amendment No. 1 amends and restates Item 5 of the Original 13D in its entirety as set forth below:

The Fund is the record owner of the Clarus Shares.  As the sole general partner of the Fund, Clarus GP may be deemed to own beneficially the Clarus Shares.  As the sole general partner of Clarus GP, Clarus GPLLC may be deemed to own beneficially the Clarus Shares.  As members of Clarus GPLLC, each of the Managing Directors may be deemed to own beneficially the Clarus Shares.

CUSIP NO.    683745103  13D Page 12 of 15 Pages 

Each Reporting Person disclaims beneficial ownership of the Clarus Shares other than those shares which such person owns of record.

The percentage of outstanding Common Stock of the Issuer which may be deemed to be beneficially owned by each Reporting Person as of the close of business on February 18, 2014 is set forth on Line 13 of such Reporting Person’s cover sheet.  Such percentage was calculated based on the 33,318,575 shares of Common Stock reported to be outstanding immediately after the Issuer’s Offering on the Issuer’s final prospectus filed under Rule 424(b)(4) with the Securities Exchange Commission on February 12, 2014.

(b) Regarding the number of shares as to which such person has:

(i) sole power to vote or to direct the vote: See line 7 of cover sheets

(ii) shared power to vote or to direct the vote: See line 8 of cover sheets

(iii) sole power to dispose or to direct the disposition: See line 9 of cover sheets.

(iv) shared power to dispose or to direct the disposition: See line 10 of cover sheets

(c) Except as set forth in Item 3 above, none of the Reporting Persons has effected any transaction in the Common Stock during the last 60 days.

(d) No other person is known to have the right to receive or the power to direct the receipt of dividends from, or any proceeds from the sale of, securities beneficially owned by any of the Reporting Persons.

(e) Not applicable.

Item 7.            Material to be Filed as Exhibits.

Exhibit 99.1 – Agreement regarding filing of joint Schedule 13D.

Exhibit 99.2 – Power of Attorney regarding filings under the Act.

CUSIP NO.    683745103  13D Page 13 of 15 Pages 

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date:      February 25, 2014

CLARUS LIFESCIENCES II, L.P.

By:   Clarus Ventures II GP, L.P., its general partner

By:   Clarus Ventures II, LLC, its general partner

By:  /s/ Robert Liptak                                     

Manager

CLARUS VENTURES II GP, L.P.

By:   Clarus Ventures II, LLC, its general partner

By:   /s/ Robert Liptak                                    

Manager

CLARUS VENTURES II, LLC

By:  /s/ Robert Liptak                                     

Manager

                                    *                                     

Nicholas Galakatos

                                    *                                     

Dennis Henner

/s/ Robert Liptak                                              

Robert Liptak

                                    *                                     

Nicholas Simon

                                    *                                     

Michael Steinmetz

                                    *                                     

Kurt Wheeler

*By:   /s/ Robert Liptak                                  

           Robert Liptak, as Attorney-in-Fact

This Amendment No. 1 to Schedule 13D was executed by Robert Liptak on behalf of the individuals listed above pursuant to a Power of Attorney a copy of which is attached as Exhibit 99.2.

CUSIP NO.    683745103  13D Page 14 of 15 Pages 

EXHIBIT 99.1

AGREEMENT

Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, the undersigned hereby agree that only one statement containing the information required by Schedule 13D need be filed with respect to the ownership by each of the undersigned of shares of Common Stock of Ophthotech Corporation.

Date:      February 25, 2014

CLARUS LIFESCIENCES II, L.P.

By:   Clarus Ventures II GP, L.P., its general partner

By:   Clarus Ventures II, LLC, its general partner

By:  /s/ Robert Liptak                                     

Manager

CLARUS VENTURES II GP, L.P.

By:   Clarus Ventures II, LLC, its general partner

By:   /s/ Robert Liptak                                    

Manager

CLARUS VENTURES II, LLC

By:  /s/ Robert Liptak                                     

Manager

                                    *                                     

Nicholas Galakatos

                                    *                                     

Dennis Henner

/s/ Robert Liptak                                              

Robert Liptak

                                    *                                     

Nicholas Simon

                                    *                                     

Michael Steinmetz

                                    *                                     

Kurt Wheeler

*By:   /s/ Robert Liptak                                  

           Robert Liptak, as Attorney-in-Fact

This Agreement was executed by Robert Liptak on behalf of the individuals listed above pursuant to a Power of Attorney a copy of which is attached as Exhibit 99.2.

CUSIP NO.    683745103  13D Page15 of 15 Pages 

EXHIBIT 99.2

POWER OF ATTORNEY

KNOW ALL BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Robert Liptak with full power to act singly, his true and lawful attorney-in-fact, with full power of substitution, to: (i) sign any and all instruments, certificates and documents that may be necessary, desirable or appropriate to be executed on behalf of himself as an individual or in his capacity as a general partner of any partnership or limited liability company, pursuant to Section 13 or 16 of the Securities Exchange Act of 1934, as amended, and any and all regulations promulgated thereunder, (ii) file the same (including any amendments thereto), with all exhibits thereto, and any other documents in connection therewith, with the Securities and Exchange Commission, and any stock exchange or similar authority and (iii) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this power of attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact’s discretion, granting unto said attorney-in-fact full power and authority to do and perform each and every act and thing necessary, desirable or appropriate.

Each of the undersigned hereby grant to the attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact or such attorney-in-fact’s substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted.

This power of attorney shall remain in full force and effect until revoked by the undersigned in a signed writing delivered to the attorney-in-fact.

IN WITNESS WHEREOF, this Power of Attorney has been signed as of the 13th day of February, 2014.

                          /s/  Nicholas Galakatos                   

  Nicholas Galakatos

  /s/ Dennis Henner                            

  Dennis Henner

  /s/ Nick Simon                                   

  Nick Simon

  /s/ Michael Steinmetz                      

  Michael Steinmetz

  /s/  Kurt Wheeler                              

  Kurt Wheeler